Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing β-amyloid precursor protein (APP) with the Swedish double mutation (APP23)

[1]  P. Kelly,et al.  Progressive age-related impairment of cognitive behavior in APP23 transgenic mice , 2003, Neurobiology of Aging.

[2]  R. D'Hooge,et al.  Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition , 2003, The European journal of neuroscience.

[3]  M. Staufenbiel,et al.  Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation , 2002, Brain Research.

[4]  D. Price,et al.  Disruption of Corticocortical Connections Ameliorates Amyloid Burden in Terminal Fields in a Transgenic Model of Aβ Amyloidosis , 2002, The Journal of Neuroscience.

[5]  Michael Costigan,et al.  Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. , 2002, BMC Neuroscience.

[6]  D. Gerhold,et al.  Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases , 2002, Neuroscience.

[7]  C. Davies,et al.  The effects of galanin on long-term synaptic plasticity in the CA1 area of rodent hippocampus , 2002, Neuroscience.

[8]  Lan Bao,et al.  Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Kelly,et al.  Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis , 2002, The Journal of Neuroscience.

[10]  Joel D Levine,et al.  Signal analysis of behavioral and molecular cycles , 2002, BMC Neuroscience.

[11]  M. Staufenbiel,et al.  Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice , 2002, The Journal of Neuroscience.

[12]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[13]  M. Staufenbiel,et al.  Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains* , 2001, The Journal of Biological Chemistry.

[14]  J. Hohmann,et al.  Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Staufenbiel,et al.  Pathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model , 2000, Annals of the New York Academy of Sciences.

[16]  V. King,et al.  Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Kehr,et al.  Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Hökfelt,et al.  Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F β-amyloid precursor protein — initial observations , 2000, Neuroscience.

[19]  M. Staufenbiel,et al.  Transgenic Mouse Models of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[20]  E. T. O. Rugarn.  Radioimmunoassay for rat galanin: immunochemical and chromatographic characterization of immunoreactivity in tissue extracts , 2000, Scandinavian journal of clinical and laboratory investigation.

[21]  M. Frotscher,et al.  Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice , 1999, The Journal of Neuroscience.

[22]  T. Hökfelt,et al.  Regulation of galanin and neuropeptide Y in dorsal root ganglia and dorsal horn in rat mononeuropathic models: possible relation to tactile hypersensitivity , 1999, Neuroscience.

[23]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[24]  B. Sommer,et al.  Association of microglia with amyloid plaques in brains of APP23 transgenic mice. , 1999, The American journal of pathology.

[25]  Sarah Tomlin,et al.  Microtechnology: Laying it on thick , 1999, Nature.

[26]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[27]  J. Kehr,et al.  Modulation of Acetylcholine and Serotonin Transmission by Galanin: Relationship to Spatial and Aversive Learning , 1998, Annals of the New York Academy of Sciences.

[28]  G. Glazner,et al.  VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar‐Acting Neuroprotective Peptide , 1998, Annals of the New York Academy of Sciences.

[29]  K. Hsiao.  Transgenic mice expressing Alzheimer amyloid precursor proteins , 1998, Experimental Gerontology.

[30]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[31]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Ma,et al.  Differential expression of galanin immunoreactivities in the primary sensory neurons following partial and complete sciatic nerve injuries , 1997, Neuroscience.

[33]  M. Staufenbiel,et al.  Amyloid precursor protein truncated at any of the γ‐secretase sites is not cleaved to β‐amyloid , 1996 .

[34]  D. Johnston,et al.  Actions of Endogenous Opioids on NMDA Receptor-Independent Long-Term Potentiation in Area CA3 of the Hippocampus , 1996, The Journal of Neuroscience.

[35]  R. Tanzi,et al.  REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease , 1996, Neurobiology of Disease.

[36]  J. Crawley.  Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease , 1996 .

[37]  C. Gottfries,et al.  Neuropeptides and Alzheimer's disease , 1995, European Neuropsychopharmacology.

[38]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[39]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[40]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[41]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[42]  T. Hökfelt,et al.  Messenger plasticity in primary sensory neurons following axotomy and its functional implications , 1994, Trends in Neurosciences.

[43]  R. Nahin,et al.  Primary sensory neurons exhibit altered gene expression in a rat model of neuropathic pain , 1994, Pain.

[44]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Benzing,et al.  Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. , 1993, Dementia.

[46]  C. Chavkin,et al.  Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus , 1993, Nature.

[47]  R. Nicoll,et al.  The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation , 1993, Nature.

[48]  K. Chihara,et al.  Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide Y in rat brain. , 1993, European journal of pharmacology.

[49]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. L. Martínez,et al.  Mu opioid receptors are associated with the induction of hippocampal mossy fiber long-term potentiation. , 1992, The Journal of pharmacology and experimental therapeutics.

[51]  Joe C. Adams,et al.  Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[52]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[53]  F. Strand,et al.  Neuropeptide hormones as neurotrophic factors. , 1991, Physiological reviews.

[54]  A. Carlsson,et al.  Hypothalamic monoamines and neuropeptides in dementia , 1991, European Neuropsychopharmacology.

[55]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[56]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[57]  W. Benzing,et al.  Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer's disease , 1989, Neuroscience.

[58]  D. Dickson,et al.  Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. , 1988, The American journal of pathology.

[59]  J. Unger,et al.  Neuropeptides and neuropathology in the amygdala in Alzheimer's disease: relationship between somatostatin, neuropeptide Y and subregional distribution of neuritic plaques , 1988, Brain Research.

[60]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[61]  M. Casanova,et al.  Neuropeptidergic Systems in Plaques of Alzheimer's Disease , 1987, Journal of neuropathology and experimental neurology.

[62]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[63]  T. Hökfelt,et al.  Striato-nigral dynorphin and substance P pathways in the rat , 1986, Experimental Brain Research.

[64]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[65]  V. Chan‐Palay,et al.  II. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's‐type dementia , 1985, The Journal of comparative neurology.

[66]  R. Terry,et al.  Substance P immunoreactivity within neuritic plaques , 1985, Neuroscience Letters.

[67]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[68]  F. Bloom,et al.  Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients , 1985, Nature.

[69]  D. Dawbarn,et al.  Neuropeptide Y-like immunoreactivity in neuritic plaques of Alzheimer's disease. , 1985, Biochemical and biophysical research communications.

[70]  L. Butcher,et al.  Alzheimer dementia and reduced nicotinamide adenine dinucleotide (NADH)-diaphorase activity in senile plaques and the basal forebrain , 1985, Neuroscience Letters.

[71]  J. Grassi,et al.  An Immunological Study of Rat Acetylcholinesterase: Comparison with Acetylcholinesterases from Other Vertebrates , 1984, Journal of neurochemistry.

[72]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[73]  P. Frey.  Cholecystokinin octapeptide (CCK 26–33), nonsulfated octapeptide and tetrapeptide (CCK 30–33) in rat brain: Analysis by high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA) , 1983, Neurochemistry International.

[74]  I. Ferrier,et al.  Neuropeptides in Alzheimer type dementia , 1983, Journal of the Neurological Sciences.

[75]  A. Michael,et al.  Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[76]  J. Barchas,et al.  Predominance of the amino-terminal octapeptide fragment of dynorphin in rat brain regions , 1982, Nature.

[77]  K. Roth,et al.  Immunohistochemical distribution of alpha-neo-endorphin/dynorphin neuronal systems in rat brain: evidence for colocalization. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[78]  F. Rose.  Metabolic Disorders of the Nervous System , 1981 .

[79]  E. Perry,et al.  Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease , 1981, Journal of the Neurological Sciences.

[80]  G. D. Johnson,et al.  A simple method of reducing the fading of immunofluorescence during microscopy. , 1981, Journal of immunological methods.

[81]  T. Hökfelt,et al.  Enkephalin immunoreactive nerve fibres and cell bodies in sympathetic ganglia of the guinea-pig and rat , 1979, Neuroscience.

[82]  O. Johansson,et al.  Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia , 1974, Science.

[83]  B. K. Hartman,et al.  The use of dopamine -hydroxylase as a marker for the central noradrenergic nervous system in rat brain. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[85]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[86]  B. Sommer,et al.  Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. , 2001, The American journal of pathology.

[87]  R. Mohney,et al.  Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor. , 1996, Perspectives on developmental neurobiology.

[88]  F. Leslie.  20 – Neurotransmitters as Neurotrophic Factors , 1993 .

[89]  J. P. Schwartz.  Neurotransmitters as neurotrophic factors: a new set of functions. , 1992, International review of neurobiology.

[90]  L. Minthon,et al.  Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. , 1990, Journal of neural transmission. Supplementum.

[91]  L. Shenkman,et al.  Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line. , 1980, Molecular pharmacology.

[92]  Coons Ah.  Fluorescent antibody methods , 1968 .